Integrating Liver & Metabolic Improvements in Patient Weight Management
- Addressing co-morbidities in obese patients
- Evaluating Icosabutate: a liver targeted, modified long chain fatty acid to improve glycaemic control, hepatic inflammation and fibrosis in MASH patients
- Identifying synergy for potential combination therapy with icosabutate and GLP-1 agonists